Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a ...

Aarti Drugs shares zoomed 12.58% to Rs 431.50 against the previous close of Rs 383.25 on BSE. Market cap of the firm climbed ...

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

This Stock Is Up 168%, but Wall Street Still Thinks It's Massively Undervalued. Here's Why.

Shares of Hims & Hers Health, the telehealth provider that has found a niche in the obesity-drug boom, surged 28% on Thursday ...

Moleculin Biotech received FDA guidance reducing its Phase 3 trial size for Annamycin in AML. First unblinding is expected in ...

Incyte has a strong track record of revenue growth and a robust pipeline, targeting over 10 high-impact product launches by ...

AbbVie shares surged nearly 8% Friday morning, after the company substantially raised its sales forecasts for two key drugs. While reporting fourth-quarter revenue and earnings per share above Wall ...